米拉贝隆对膀胱过度活动症女性患者焦虑和抑郁的影响。
Effects of Mirabegron on Anxiety and Depression in Female Patients with Overactive Bladder.
作者信息
Kinjo Manami, Yamaguchi Tsuyoshi, Tambo Mitsuhiro, Okegawa Takatsugu, Fukuhara Hiroshi
机构信息
Department of Urology, Kyorin University School of Medicine, Tokyo, Japan,
Department of Urology, Kyorin University School of Medicine, Tokyo, Japan.
出版信息
Urol Int. 2019;102(3):331-335. doi: 10.1159/000497282. Epub 2019 Feb 21.
BACKGROUND
Treatment of overactive bladder (OAB) with antimuscarinic agents has been shown to improve depression and/or anxiety symptoms.
OBJECTIVES
The aim of this study was to evaluate the efficacy of mirabegron on OAB symptoms and its effects on depression and/or anxiety of treatment-naïve women with OAB.
METHODS
Women treated with mirabegron were prospectively evaluated by the OAB symptom score and hospital anxiety and depression Scale before and at 4 and 8 weeks after treatment. Wilcoxon signed-rank and Spearman rank correlation coefficient were used for statistical analyses, and a p value of < 0.05 was considered as significant.
RESULTS
Of the 112 patients who were enrolled, 25.0% had been previously diagnosed as having clinical anxiety and 22.3% as having clinical depression. The OAB, anxiety, and depression symptom scores were significantly improved at both 4 and 8 weeks (p < 0.05). Anxiety, but not depression, symptoms were significantly correlated with OAB symptoms.
CONCLUSION
Improvement of OAB symptoms helps relieve anxiety, but not depression.
背景
已证明使用抗毒蕈碱药物治疗膀胱过度活动症（OAB）可改善抑郁和/或焦虑症状。
目的
本研究旨在评估米拉贝隆对初治OAB女性患者的OAB症状疗效及其对抑郁和/或焦虑的影响。
方法
对接受米拉贝隆治疗的女性患者在治疗前、治疗后4周和8周时通过OAB症状评分及医院焦虑抑郁量表进行前瞻性评估。采用Wilcoxon符号秩检验和Spearman秩相关系数进行统计分析，p值<0.05被认为具有统计学意义。
结果
在纳入的112例患者中，25.0%既往被诊断为临床焦虑，22.3%既往被诊断为临床抑郁。在4周和8周时，OAB、焦虑和抑郁症状评分均显著改善（p<0.05）。焦虑症状而非抑郁症状与OAB症状显著相关。
结论
OAB症状的改善有助于缓解焦虑，但不能缓解抑郁。
Zotero 插件